HomeBody MapPeptidesCalculator
Catalog11 refs

GHRP-2

Growth Hormone SecretagogueGrowth Hormone / IGF-1 AxistherapeuticMetabolicGrowth HormoneResearch use only
Educational use only. Not medical advice. Verify all information with primary sources and a licensed clinician before use.
~1.5 Hours
Half-life
24
Uses
100
Typical
Body Map
Loading 3D model…
MusclesSkin
Overview

GHRP-2 (generic name pralmorelin) is a synthetic hexapeptide growth hormone secretagogue and a second-generation cousin of GHRP-6. It is an agonist at the ghrelin / growth hormone secretagogue receptor (GHS-R1a), binding that receptor in the pituitary and hypothalamus to drive a pulse of growth hormone release. It was designed to be more potent and somewhat cleaner than GHRP-6, with a milder effect on appetite. It is licensed in Japan as a diagnostic agent for growth hormone deficiency, making it the only GH secretagogue in this class with regulatory approval. Outside that narrow diagnostic use it has no approval and is sold elsewhere only as a research compound.

Primary Uses
Growth hormone deficiency
Cachexia
Growth hormone release stimulation
Muscle growth and strength
muscle growth
anti-aging
GH deficiency diagnosis
GH release studies
IGF-1 modulation
Appetite and ghrelin research
Combination secretagogue protocols
GH Deficiency Assessment
Natural GH Stimulation
IGF-1 Elevation
Fat Metabolism
Recovery Enhancement
Muscle Protection
Cardioprotection
Growth hormone research
Fat loss
Growth hormone deficiency diagnosis
Body composition (off-label/unproven)
Anti-aging (off-label/unproven)
Recovery (off-label/unproven)
Protocol Reference
Dose
100–300mcg per injection
Frequency
2-3 times daily
Half-life
~1.5 Hours
Route
Injection
Evidence
Phase 2 / Approved (Japan, diagnostic) / Well Studied / Preclinical (disputed)
Research References· 7
On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone
PubMedPMID 6432051. Endocrinology, 1984.
Endocrine activities of ghrelin, a natural growth hormone secretagogue (GHS), in humans: comparison and interactions with hexarelin, a nonnatural peptidyl GHS, and GH-releasing hormone
PubMedPMID 11158035. Journal of Clinical Endocrinology & Metabolism, 2001.
Growth hormone secretagogues: history, mechanism of action, and clinical development
PubMedPMID 33345175. JCSM Rapid Communications, 2020.
Research Models
Human
Also in Growth Hormone Secretagogue
Growth Hormone Secretagogue
CJC-1295
Muscle growth · Anti-aging
Growth Hormone Secretagogue
CJC-1295 (Modified GRF 1-29)
Growth hormone release · Body composition improvement
Growth Hormone Secretagogue
CJC-1295 with DAC
Sustained growth hormone elevation · Increasing IGF-1 levels
Growth Hormone Secretagogue
CJC-1295/Ipamorelin
Muscle Growth · Enhanced Protein Synthesis
Compare